The CCM2 Knockout Huh-7 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population generated from the Huh-7 human hepatocellular carcinoma cell line, with targeted disruption of the CCM2 gene. Unlike clonal lines, this polyclonal format encompasses a heterogeneous pool of gene-edited cells, minimizing clonal selection artifacts and preserving the polygenic background of the parental line, making it suitable for reproducible cell culture assays.
The Huh-7 cell line was originally isolated from a liver tumor of a 57-year-old male and has since become a standard model for hepatocellular carcinoma, hepatic metabolism, and hepatocyte biology. This adherent epithelial line retains many differentiated hepatocyte features and is widely used in studies of hepatic signal transduction, drug metabolism, and tumor cell migration, offering a robust platform for gene function analysis in a liver-cancer context.
CCM2 encodes a scaffold protein that forms the core of the CCM signaling complex, interacting with CCM1 (KRIT1), CCM3 (PDCD10), ICAP1, and MEKK3 to negatively regulate RhoA and its downstream effectors ROCK1/2, thereby maintaining endothelial junction integrity. It also modulates MAPK/ERK and p38 MAPK pathways through direct MEKK3 binding. Upstream regulators include integrin signaling, VEGF, and FAK; downstream targets encompass ERM proteins and RAC1. Loss of CCM2 disinhibits RhoA, leading to stress fiber formation, compromised cell-cell contacts, and vascular malformation pathology.
In the Huh-7 hepatocellular carcinoma background, CCM2 disruption provides a unique model to dissect CCM complex functions in hepatic cell signaling, migration, and junction dynamics. Although CCM mutations are primarily associated with cerebral vascular lesions, the complex also influences epithelial cell migration, proliferation, and apoptosis. This polyclonal knockout population avoids clonal adaptation artifacts and better captures tumor heterogeneity, making it valuable for both cancer research and vascular biology studies that intersect with hepatic physiology.
Typical experimental applications include Western blotting and RT-qPCR for confirming CCM2 ablation and assessing downstream effectors, immunofluorescence to visualize junctional protein localization and stress fiber formation, Rho GTPase activation assays to quantify active RhoA levels, and cell migration or invasion assays using transwell or wound-healing formats. Flow cytometry can be applied to analyze apoptosis or surface marker expression in the mixed population. These cells are particularly suited for studying CCM2 function in hepatic signaling, exploring CCM complex-dependent regulation of cell motility in hepatocellular carcinoma, and modeling aspects of vascular biology using a hepatic cell surrogate. For comprehensive product support and ordering, please contact Ascent Research.
